Last reviewed 2026-04-20 · How we verify

Chemotherapy Regimen 2 (chemotherapy-regimen-2)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Anemia
• Neutrophil count decreased
• Creatinine increased
• Fatigue
• Peripheral sensory neuropathy
• Platelet count decreased
• Diabetic retinal oedema Study Eye
• Hypertension
• Nausea
• acute graft-versus-host disease
• Diabetic retinopathy Study Eye
• Urinary tract infection

Key clinical trials

• Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
• A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (PHASE1)
• Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (PHASE2)
• Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients (PHASE3)
• A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
• Volrustomig Priming Regimens Exploratory Phase II Platform Study (PHASE2)
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.